investorscraft@gmail.com

Altimmune, Inc. (ALT)

Previous Close
$3.50
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)72.341967
Intrinsic value (DCF)0.16-95
Graham-Dodd Methodn/a
Graham Formula111.283080

Company Information

910 Clopper Road
Gaithersburg, MD 20878
United States
Phone: 240 654 1450
Industry: Biotechnology
Sector: Healthcare
CEO: Dr. Vipin K. Garg Ph.D.
Full Time Employees: 59

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

HomeMenuAccount